Matthias Held

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 490 citations · Full text

Antifibrotic Therapy, Advanced Lung Disease, Idiopathic Pulmonary Fibrosis +6

Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry

Marius M. Hoeper, Dörte Huscher, Hossein Ardeschir Ghofrani et al. · International Journal of Cardiology · 2012 · 447 citations

Hypertension, Heart Failure, Compera Registry +13

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension

Marius M. Hoeper, Christine Pausch, Karen M. Olsson et al. · European Respiratory Journal · 2021 · 309 citations · Full text

RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Hossein Ardeschir Ghofrani, Gérald Simonneau, Andrea Maria D’Armini et al. · The Lancet Respiratory Medicine · 2017 · 262 citations

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

Jürgen Behr, Michael Kreuter, Marius M. Hoeper et al. · European Respiratory Journal · 2015 · 230 citations · Full text